{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:38:36Z","timestamp":1780504716234,"version":"3.54.1"},"reference-count":17,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0205368","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T20:05:43Z","timestamp":1540325143000},"page":"e0205368","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":39,"title":["Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir\/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial"],"prefix":"10.1371","volume":"13","author":[{"given":"Javier","family":"Morales-Ramirez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes R.","family":"Bogner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lombaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira B.","family":"Dicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"DeGrosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Gartland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Pene Dumitrescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherene","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Llamoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samit R.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6103-8967","authenticated-orcid":true,"given":"Max","family":"Lataillade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,10,23]]},"reference":[{"key":"ref1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/aidsinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-arv\/0\" xlink:type=\"simple\">https:\/\/aidsinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-arv\/0<\/ext-link>. Cited 1 November 2017."},{"key":"ref2","unstructured":"AIDSinfo. FDA-approved HIV medicines. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/aidsinfo.nih.gov\/education-materials\/fact-sheets\/21\/58\/fda-approved-hiv-medicines\" xlink:type=\"simple\">https:\/\/aidsinfo.nih.gov\/education-materials\/fact-sheets\/21\/58\/fda-approved-hiv-medicines<\/ext-link>. Cited 1 November 2017."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"10226","DOI":"10.1128\/JVI.76.20.10226-10233.2002","article-title":"Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease","volume":"76","author":"SC Pettit","year":"2002","journal-title":"J Virol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1128\/JVI.72.4.2846-2854.1998","article-title":"Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites","volume":"72","author":"K Wiegers","year":"1998","journal-title":"J Virol"},{"key":"ref5","first-page":"162","article-title":"Maturation inhibitors: a new therapeutic class targets the virus structure","volume":"9","author":"K Salzwedel","year":"2007","journal-title":"AIDS Rev"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1128\/JVI.78.2.922-929.2004","article-title":"Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation","volume":"78","author":"J Zhou","year":"2004","journal-title":"J Virol"},{"key":"ref7","first-page":"759","article-title":"Drug evaluation: bevirimat\u2014HIV Gag protein and viral maturation inhibitor","volume":"7","author":"Z Temesgen","year":"2006","journal-title":"Curr Opin Investig Drugs"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/095632020801900301","article-title":"Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection","volume":"19","author":"DE Martin","year":"2008","journal-title":"Antivir Chem Chemother"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1128\/AAC.01784-09","article-title":"Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat","volume":"54","author":"NA Margot","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref10","unstructured":"Knapp DJHF, Huang S, Harrigan PR. Stable prevalence of bevirimat-related HIV gag polymorphisms both before and after HAART exposure. Proceedings of the 16th Conference on Retroviruses and Opportunistic Infections; 8\u201311 Feb 2009; Montreal, Canada."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1128\/AAC.01650-08","article-title":"Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1","volume":"53","author":"K Van Baelen","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1742-4690-7-36","article-title":"Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat","volume":"7","author":"CS Adamson","year":"2010","journal-title":"Retrovirology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1128\/AAC.00152-07","article-title":"Phase I and II study of the safety, virologic effect, and pharmacokinetics\/pharmacodynamics of single-dose 3-o-(3&apos;,3&apos;-dimethylsuccinyl) betulinic acid (bevirimat) against human immunodeficiency virus infection","volume":"51","author":"PF Smith","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/cid\/cix239","article-title":"Antiviral activity, safety, and exposure-response relationships of GSK3532795, a second-generation HIV-1 maturation inhibitor, administered as monotherapy or in combination with atazanavir+\/-ritonavir in a Phase 2a randomized, dose-ranging, controlled trial (AI468002)","volume":"65","author":"C Hwang","year":"2017","journal-title":"Clin Infect Dis"},{"key":"ref15","unstructured":"Dicker I, Nowicka-Sans B, Zhang S, Ray N, Beno B, Regueiro-Ren A, et al. Resistance profile of HIV-1 maturation inhibitor GSK3532795. 26th International Workshop on HIV Drug Resistance and Treatment Strategies; 6\u20138 Nov 2017; Johannesburg, South Africa."},{"key":"ref16","author":"H Brown","year":"1999"},{"key":"ref17","unstructured":"Beal SL, Sheiner LB, Boeckmann AJ. NONMEMUsersGuide: Part I-VII (Icon Development Solutions, Ellicott City,Maryland, USA, 1989\u20132006)."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0205368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T22:02:38Z","timestamp":1605304958000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0205368"}},"subtitle":[],"editor":[{"given":"Giuseppe Vittorio","family":"De Socio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,10,23]]},"references-count":17,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0205368","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,23]]}}}